NEW YORK, Sept. 6, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Dynavax Technologies Corporation ("Dynavax" or the
"Company") (NASDAQ: DVAX). Such investors are advised to contact
Peretz Bronstein or his investor
relations analyst, Yael Hurwitz at
info@bgandg.com or 212-697-6484.
The investigation concerns whether Dynavax and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On September 2, 2016, the U.S.
Food and Drug Administration ("FDA") revealed that it has cancelled
Dynavax's upcoming meeting with the Vaccines and Related Biological
Products Advisory Committee, that was scheduled for November 16, 2016, "to allow time for the FDA to
review and resolve several outstanding issues" with Dynavax's
Biologics License Application for HEPLISAV-B™. The FDA said that if
necessary it would reschedule a meeting. Following this news
Dynavax stock dropped $5.03, or 32%,
to close at $10.91per share on
September 2, 2016.
If you purchased Dynavax shares or if you are aware of any facts
relating to this investigation, you can assist this investigation
by visiting the firm's site: http://www.bgandg.com/dvax. You can
also contact Peretz Bronstein or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC:
212-697-6484 or via email info@bgandg.com. Those who inquire
by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-dynavax-technologies-corporation-dvax-300322515.html
SOURCE Bronstein, Gewirtz & Grossman, LLC